HSA Adverse Drug Reaction News 2018 Dec, Vol.20 No.3

HSA Adverse Drug Reaction News 2018 Dec, Vol.20 No.3

The aim of the news bulletin is to increase the awareness of adverse events related to health products amongst healthcare professionals, and to promote adverse event reporting related to health products.

• ADR_News_Dec_2018_Vol20_No3 [PDF, 1.8 MB]

This issue includes the following topics: 

• Potential risk of new primary malignancy with Xgeva®

• Early termination of ALLOZITHRO trial due to increased risk of relapse in haematopoietic stem cell transplantation patients treated with azithromycin for prophylaxis of bronchiolitis obliterans syndrome

• Adverse event reports of liver injury suspected with the use of mahogany seeds

• Highlights on drug-AE pairs of interest reviewed by HSA for the year 2018

• Updates on adulterated products used for pain relief reported to HSA

• List of Dear Healthcare Professional Letters (1 Sep 2018 – 30 Nov 2018)

• WHO-UMC-HSA Inter-regional Pharmacovigilance Training Workshop 2018